Bladder management in multiple sclerosis

Physical Medicine and Rehabilitation Clinics of North America

Volumn 24, Issue 4, 2013, Pages 673-686

  Yang, Claire C ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Bladder; Neurogenic bladder; Treatment; Urinary tract

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; BOTULINUM TOXIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; DESMOPRESSIN; IMIPRAMINE; MUSCLE RELAXANT AGENT; NARCOTIC AGENT; NORTRIPTYLINE; OXYBUTYNIN; SOLIFENACIN; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; TROSPIUM CHLORIDE;

BEHAVIOR MODIFICATION; BLADDER CONTRACTION; BLADDER EMPTYING; BLADDER NECK STENOSIS; BLADDER RECONSTRUCTION; CATHETERIZATION; CHRONIC INDWELLING CATHETERIZATION; CLEAN INTERMITTENT CATHETERIZATION; CONSTIPATION; DIET RESTRICTION; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG MECHANISM; FEEDBACK SYSTEM; FLUID INTAKE; HUMAN; ILEAL CONDUIT; INTERMITTENT CATHETERIZATION; LOW DRUG DOSE; MICTURITION; MORNING DOSAGE; MULTIPLE SCLEROSIS; NEUROGENIC BLADDER; NEUROMODULATION; OVERACTIVE BLADDER; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PHYSIOTHERAPY; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; UNSPECIFIED SIDE EFFECT; URETHRA; URETHRAL SLING; URINARY DIVERSION; URINARY TRACT FUNCTION; URINARY TRACT SURGERY; URINE RETENTION; UROLOGICAL CARE; VALSALVA MANEUVER;

BLADDER; NEUROGENIC BLADDER; TREATMENT; URINARY TRACT;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; BEHAVIOR THERAPY; BOTULINUM TOXINS; CHOLINERGIC ANTAGONISTS; ELECTRIC STIMULATION THERAPY; HUMANS; MULTIPLE SCLEROSIS; URINARY BLADDER, NEUROGENIC; URINARY CATHETERIZATION; URINARY DIVERSION; URINARY TRACT; URINARY TRACT PHYSIOLOGICAL PHENOMENA;

EID: 84886590363     PISSN: 10479651     EISSN: 15581381     Source Type: Journal    
DOI: 10.1016/j.pmr.2013.06.004     Document Type: Review

References (18)

1. de Seze M., Ruffion A., Denys P., et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 2007, 13(7):915-928.
2. Mahajan S.T., Patel P.B., Marrie R.A. Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry. JUrol 2010, 183(4):1432-1437.
3. Fowler C.J., Panicker J.N., Drake M., et al. AUK consensus on the management of the bladder in multiple sclerosis. JNeurol Neurosurg Psychiatry 2009, 80(5):470-477.
4. Urinary dysfunction and multiple sclerosis: evidence-based management strategies for urinary dysfunction and multiple sclerosis. Multiple Sclerosis Council practice guidelines: Washington, DC; 1999.
5. Stoffel J.T. Contemporary management of the neurogenic bladder for multiple sclerosis patients. Urol Clin North Am 2010, 37(4):547-557.
6. Tubaro A., Puccini F., De Nunzio C., et al. The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review. Curr Urol Rep 2012, 13(5):335-342.
7. Loening-Baucke V. Urinary incontinence and urinary tract infection and their resolution with treatment of chronic constipation of childhood. Pediatrics 1997, 100(2 Pt 1):228-232.
8. Klarskov P., Heely E., Nyholdt I., et al. Biofeedback treatment of bladder dysfunction in multiple sclerosis. A randomized trial. Scand J Urol Nephrol Suppl 1994, 157:61-65.
9. Patil N.J., Nagaratna R., Garner C., et al. Effect of integrated Yoga on neurogenic bladder dysfunction in patients with multiple sclerosis-A prospective observational case series. Complement Ther Med 2012, 20(6):424-430.
10. Coelho A., Dinis P., Pinto R., et al. Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder. Eur Urol 2010, 57(5):884-890.
11. Reitz A., Stohrer M., Kramer G., et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004, 45(4):510-515.
12. Karsenty G., Denys P., Amarenco G., et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 2008, 53(2):275-287.
13. Bosma R., Wynia K., Havlikova E., et al. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand 2005, 112(1):1-5.
14. Leng W.W., Chancellor M.B. How sacral nerve stimulation neuromodulation works. Urol Clin North Am 2005, 32(1):11-18.
15. Wallace P.A., Lane F.L., Noblett K.L. Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol 2007, 197(1):96.e91-96.e95.
16. Minardi D., Muzzonigro G. Sacral neuromodulation in patients with multiple sclerosis. World J Urol 2012, 30(1):123-128.
17. Kabay S., Kabay S.C., Yucel M., et al. The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. Neurourol Urodyn 2009, 28(8):964-968.
18. Awad S.A., Gajewski J.B., Sogbein S.K., et al. Relationship between neurological and urological status in patients with multiple sclerosis. JUrol 1984, 132(3):499-502.